| Home | Search Abstracts | Browse Sessions | Program Committee | Conference Webcasts | Contact Us |
|
Session 93
Poster Abstracts Interplay between STI's and Drug Resistance Tuesday, 1:30 - 3:30 pm Poster Hall |
| 663 | Changes in T-cell Activation and CD4 Counts during Partial Treatment Interruption of Protease Inhibitor Therapy P W Hunt*1, J N Martin1, E Sinclair1, B Bredt1, R Ho1, G Tsao1, T B Neilands1, C Petropolous2, R M Grant3, and S G Deeks1 1Univ. of California, San Francisco, USA; 2ViroLogic Inc., South San Francisco, CA, USA; and 3Gladstone Inst. of Virology and Immunology, San Francisco, CA, USA |
| 664 | Purging of Monocytes Improves the Virological and Immunological Response to HAART Reintroduction after Structured Treatment Interruptions in HIV-infected Multiple Drug-resistant Patients H Hasson1, P Biswas1, B Mantelli1, S Nozza1, A Vecchi1, M Malnati2, S Saniabadi3, A Lazzarin1, and A Beretta*1 1Infectious Diseases Clinic. S.Raffaele Hosp.. Milan.Italy; 2DIBIT, S. Raffaele Sci. Inst., Milan, Italy; and 3Japan ImmunoRes. Inst., Takasaki, Japan |
| 665 | Changes in HIV-resistance Patterns during Structured Treatment Interruption: CPCRA 064 J Lawrence1, K Huppler Hullsiek*2, D Abrams1, J Baxter3, and CPCRA 064 1Univ. of California, San Francisco, USA; 2Univ. of Minnesota, Minneapolis, USA; and 3Cooper Hosp./RWJ Med. Sch. |
| 666 | Comparison of the Dynamics of Resistance-associated Mutations to NRTI, NNRTI, and PI after Cessation of Antiretroviral Combination Therapy M Wirden*, B Amellal, C Delaugerre, A G Marcelin, N Ktorza, H Ait-Mohand, L Schneider, C Katlama, and V Calvez Pitié-Salpêtrière Hosp., Paris, France |
| 667 | Viral Populations with Distinct Drug-resistant Genotypes Shift during Repeated Structured Treatment Interruptions G Ellis*1, W Borkowsky2, R Yogev3, B Ank4, P Muresan5, T Fenton5, B Heckman6, E McFarland7, E Capparelli8, J Moye9, S Jankelevich9, L Frenkel1, and the PACTG 1Univ. of Washington, Seattle, USA; 2New York Univ. Sch. of Med., NY, USA; 3Children's Mem. Hosp., Chicago, IL, USA; 4Univ. of California, Los Angeles, Sch. of Med., USA; 5Frontier Sci. and Technology Res. Fndn.-Harvard Sch. of Publ. Hlth., Boston, MA, USA; 6Frontier Sci. and Technology Res. Fndn.-Data Management Ctr., Amherst, NY, USA; 7Univ. of Colorado Hlth. Sci. Ctr., Denver, USA; 8Univ. of California, San Diego, USA; and 9NICHD, NIH, DHHS, Bethesda, MD, USA |
| 668 | Risk of Developing Selected de novo Resistance Mutations during Structured Therapy Interruption in Chronic HIV-1 Infection. M Arnedo-Valero*, F Garcia, C Gil, P Castro, J L Blanco, J M Miro, T Pumarola, and J M Gatell IDIBAPS, Hosp. Clin. Barcelona, Univ. of Barcelona, Spain |
